一级预防患者中抗心动过速起搏的评估:APPRAISE ATP随机临床试验
这项全球前瞻性双盲随机临床试验纳入2595例一级预防ICD适应证患者,1:1随机接受抗心动过速起搏(ATP)加电击或仅电击。平均随访38个月,ATP加电击组首次全因电击风险低于仅电击组(HR 0.72,95.9%CI 0.57-0.92,P=.005)。结论认为在采用现代ICD检测程控的一级预防ICD recipients中,电击前单次burst ATP延长了首次全因ICD电击时间。
要点
- 一级预防ICD患者中,ATP加电击较仅电击降低首次全因电击风险(HR 0.72)。
- 平均随访38个月,ATP加电击组首次全因电击129例,仅电击组178例。
- 每100患者年总电击负担两组无统计学差异(12.3 vs 14.9,P=.70)。
核心结论
- 在采用现代ICD检测程控的一级预防ICD recipients中,电击前使用单次burst ATP延长了首次全因ICD电击时间。
研究设计与样本
- 全球、前瞻性、双盲、随机临床试验,采用等效性设计,相对界值为35%。
- 2016年9月至2021年4月在8个国家134个中心入组患者,末次随访日期为2023年7月6日。
- 患者须有一级预防ICD适应证,包括左心室射血分数小于或等于35%。
- 共2595例患者按1:1随机接受ATP加电击或仅电击,平均年龄63.9岁,女性占22.4%。
主要发现
- 平均随访38个月,ATP加电击组首次全因电击129例,仅电击组178例。
- 主要终点风险比HR 0.72(95.9%CI 0.57-0.92),P=.005,ATP加电击组优于仅电击组。
- 意向性治疗分析中,每100患者年总电击负担ATP加电击组12.3 vs 仅电击组14.9,无统计学差异(P=.70)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The emergence of novel programming guidelines that reduce premature and inappropriate therapies along with the availability of new implantable cardioverter-defibrillator (ICD) technologies lacking traditional endocardial antitachycardia pacing (ATP) capabilities requires the reevaluation of ATP as a first strategy in terminating fast ventricular tachycardias (VTs) in primary prevention ICD recipients. OBJECTIVE: To assess the role of ATP in terminating fast VTs in primary prevention ICD recipients with contemporary programming. DESIGN, SETTING, AND PARTICIPANTS: This global, prospective, double-blind, randomized clinical trial had an equivalence design with a relative margin of 35%. Superiority tests were performed at interim analyses and the final analysis if equivalence was not proven. Patients were enrolled between September 2016 and April 2021 at 134 sites in 8 countries, with the last date of follow-up on July 6, 2023. Patients were required to have an indication for a primary prevention ICD, including left ventricular ejection fraction less than or equal to 35%. INTERVENTIONS: Patients were randomized in a 1:1 ratio to receive ATP plus shock vs shock only. MAIN OUTCOMES AND MEASURES: The primary end point was time to first all-cause shock. Secondary end points included time to first appropriate shock, time to first inappropriate shock, all-cause mortality, and the composite of time to first all-cause shock plus all-cause mortality. RESULTS: A total of 2595 patients were randomized (mean age, 63.9 years; 22.4% were females). At a mean follow-up of 38 months, first all-cause shock occurred in 129 participants in the ATP plus shock group and 178 participants in the shock only group. The hazard ratio (HR) for the primary end point was 0.72 (95.9% CI, 0.57-0.92), with P = .005 for superiority of the ATP plus shock group over the shock only group. During follow-up in an intention-to-treat analysis, the total shock burden per 100 patient-years was not statistically different, at 12.3 and 14.9, respectively (P = .70). CONCLUSIONS AND RELEVANCE: The use of a single burst of ATP prior to shock in primary prevention ICD recipients with modern ICD detection programming prolonged the time to first all-cause ICD shock. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02923726.
引用
- Schuger C, Joung B, Ando K, et al. Assessment of Antitachycardia Pacing in Primary Prevention Patients: The APPRAISE ATP Randomized Clinical Trial. JAMA. 2024. PMID: 39361311. doi:10.1001/jama.2024.16531
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。